Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real-world data.

Erika Paige  Hamilton

Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Flatiron Health; Genentech/Roche (Inst); Lilly (Inst); Mersana (Inst); Pfizer (Inst); Puma Biotechnology (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ArQule (Inst); AstraZeneca (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Cascadian Therapeutics (Inst); Clovis Oncology (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Fujifilm (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Hutchison MediPharma (Inst); Immunomedics (Inst); InventisBio (Inst); Kadmon (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); Mallinckrodt (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Novartis (Inst); Nucana (Inst); OncoMed (Inst); Oncothyreon (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); TetraLogic Pharmaceuticals (Inst); Verastem (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Foundation Medicine; Genentech; Genentech/Roche; Genzyme; Guardant Health; Helsinn Therapeutics; HERON; Lexicon; Lilly; Lilly; Medivation; Merck; Novartis; Pfizer; Roche; Sysmex; Tesaro

Valerie Malyvanh  Jansen

Employment - Lilly

Stock and Other Ownership Interests  - Lilly

Emily Nash  Nash Smyth

Employment - Lilly

Stock and Other Ownership Interests  - Lilly

Research Funding - Lilly

Other Relationship - Lilly

Daniel  Schlauch

No Relationships to Disclose

Gebra  Cuyun Carter

Employment - Lilly

Stock and Other Ownership Interests  - Lilly

Melinda D  Willard

Employment - Lilly

Stock and Other Ownership Interests  - Lilly

Amanda  Misch

Employment - HCA Healthcare

Lee  Bowman

Employment - Lilly

Stock and Other Ownership Interests  - Lilly

Yajun Emily  Zhu

Employment - Lilly

Samuel  McNeely

Employment - Lilly

Stock and Other Ownership Interests  - Lilly

Research Funding - Lilly

Travel, Accommodations, Expenses - Lilly

Aimee Bence  Lin

Employment - Lilly; Lilly (I)

Stock and Other Ownership Interests  - Lilly; Lilly (I)

Shaita  Picard

Employment - Sarah Cannon Research Institute

Travel, Accommodations, Expenses - Sarah Cannon Research Institute

Kimberly  Blackwell

No Relationships to Disclose

Howard A.  Burris

Employment - HCA Healthcare

Leadership - HCA Healthcare

Stock and Other Ownership Interests  - HCA Healthcare

Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)

Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Harpoon therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)

Expert Testimony - Novartis

David R.  Spigel

Leadership - TriStar Centennial Medical Center

Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Evelo Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Precision Oncology (Inst); Takeda (Inst); TRM Oncology (Inst)

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Pfizer (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genzyme; Intuitive Surgical; Lilly; Merck; Pfizer; Purdue Pharma; Spectrum Pharmaceuticals; Sysmex